Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk in Phase 3 Trial
A Phase 3 trial presented at ESMO 2026 found that adding a personalized mRNA vaccine to Keytruda after melanoma surgery lowered the risk of the cancer returning. Overall survival has not yet differed significantly, and the full peer-reviewed paper is still to come.
FDA Approves Hibsago, a First-of-Its-Kind Hepatitis B Drug That Lets Some Patients Stop Treatment
The FDA has approved Hibsago (bepirovirsen), GSK's injectable antisense drug for chronic hepatitis B. In two phase 3 trials, about 19% of patients achieved a functional cure and could stop all treatment. The drug carries a boxed warning for liver reactions and low platelets.
FDA Grants Accelerated Approval to Dostarlimab for dMMR Rectal Cancer, Opening a Path Around Surgery
The FDA has cleared GSK's immunotherapy Jemperli for a small, genetically defined group of patients with locally advanced rectal cancer. In trials, many avoided surgery, radiation and chemotherapy entirely, but the evidence comes from single-arm studies and longer follow-up is still required.
EU Regulators Back Daraxonrasib, the Pill That Nearly Doubled Survival in Advanced Pancreatic Cancer
Europe's medicines committee has recommended approval of daraxonrasib, an oral RAS-targeting drug for metastatic pancreatic cancer. In a 500-patient phase 3 trial, it extended median survival from 6.7 to 13.2 months compared with chemotherapy. Here is what the data show and what remains uncertain. On 26 August 2026, the FDA approved the oral drug daraxonrasib. Former US Senator Ben Sasse took it for stage 4 pancreatic cancer. It shrank his tumors and left him with a nasty bleeding skin rash.